Contrasting Forward Pharma A/S (FWP) & Its Peers
Forward Pharma A/S (NASDAQ: FWP) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Forward Pharma A/S to related businesses based on the strength of its earnings, dividends, valuation, institutional ownership, analyst recommendations, risk and profitability.
This is a summary of current ratings and price targets for Forward Pharma A/S and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Forward Pharma A/S||0||2||1||0||2.33|
|Forward Pharma A/S Competitors||1377||4466||12277||311||2.63|
Forward Pharma A/S presently has a consensus price target of $25.00, indicating a potential upside of 302.58%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.25%. Given Forward Pharma A/S’s higher possible upside, analysts plainly believe Forward Pharma A/S is more favorable than its rivals.
Valuation and Earnings
This table compares Forward Pharma A/S and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Forward Pharma A/S||N/A||-$55.33 million||-8.75|
|Forward Pharma A/S Competitors||$464.68 million||$167.54 million||-6.57|
Forward Pharma A/S’s rivals have higher revenue and earnings than Forward Pharma A/S. Forward Pharma A/S is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Forward Pharma A/S and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Forward Pharma A/S||N/A||-31.89%||-30.50%|
|Forward Pharma A/S Competitors||-4,766.74%||-354.83%||-43.39%|
Forward Pharma A/S pays an annual dividend of $23.07 per share and has a dividend yield of 371.5%. Forward Pharma A/S pays out -3,249.3% of its earnings in the form of a dividend. As a group, “Bio Therapeutic Drugs” companies pay a dividend yield of 10.8% and pay out 152.8% of their earnings in the form of a dividend. Forward Pharma A/S is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
Insider & Institutional Ownership
21.9% of Forward Pharma A/S shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Forward Pharma A/S has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Forward Pharma A/S’s rivals have a beta of 6.57, indicating that their average share price is 557% more volatile than the S&P 500.
Forward Pharma A/S rivals beat Forward Pharma A/S on 8 of the 14 factors compared.
About Forward Pharma A/S
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis. The Company’s DMF formulation, FP187, employs over two methods, which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels, which, in turn, controls DMF’s side effects. The Company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.
Receive News & Stock Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related stocks with our FREE daily email newsletter.